In This Section

COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics

Sunday April 03, 2022

8:00 am - 9:30 am Eastern Time (ET)



DMDD TOX

Chair :

Maria Croyle
University of Texas at Austin

Kerry Goralski
Dalhousie University



Acute infection and inflammation transiently suppress hepatic drug metabolism. This session will discuss clinical cases supporting altered pharmacokinetics of small molecules and biologics following SARS-CoV-2 infection or immunization and examine the mechanisms of interactions between the innate immune response and small molecule and biologic metabolism following SARS-CoV-2 infection or immunization. Understanding the impact of emerging infections and vaccine technologies on drug metabolism will help mitigate drug toxicity and improve drug and vaccine safety and effectiveness.

Speakers

William Honer - University of British Columbia

A Case Report Exploring the Possibility of SARS-CoV-2 Vaccination Increasing Clozapine Levels

Clozapine is unique among medications in providing benefit for patients who have poor responses to other antipsychotics. Neurologic toxicity associated with high clozapine levels can occur in patients with infections such as pneumonia or COVID-19, possibly mediated through cytokines or acute phase proteins such as CRP inhibiting clozapine metabolism. The possibility that vaccines could alter CYP1A2 activity and affect clozapine levels will be discussed with reference to a case report of transiently high clozapine levels following SARS-CoV-2 vaccination.

William Zamboni - University of North Carolina - UNC Eshelman School of Pharmacy

Effect of COVID-19 Infection on the Innate Immune System and the Disposition of Complex Drugs

Drug metabolism and disposition can be altered by the innate immune system (IIS), which is the primary clearance pathway for complex drugs (e.g. nanoparticles and biologics). Patients with COVID-19 infections may have altered IIS function and phenotypes, which inhibit the clearance of nanoparticles and biologics and put these patients at higher risk for drug related toxicities. In this talk results from ADME studies conducted in COVID19 patients with characterized IIS profiles will be discussed.

Maria Croyle - University of Texas at Austin - Department of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy

Impact of Emerging Infections and Vaccines on CYP450 Metabolism

People with highest risk of complications from COVID19 are those with underlying medical conditions (cardiovascular disease, diabetes, hypertension, chronic lung disease) all of which require use of several medicinal agents for maintenance therapy. Approximately one third of those that recover from SARS-CoV-2 infection experience compromised hepatic function, suggesting that potentially long-term alteration of drug metabolism and excretion. This talk will provide an overview of the impact of virus infection and emergency use vaccines on hepatic CYP450 expression and function and will discuss genomic and proteomic signatures collected from animal models of SARS-CoV-2 infection during infection and after recovery.

Talks will be selected from submitted abstracts.

Last Updated: August 31, 2021
Key Dates
 
November 30, 2021

Abstract Submission Deadline

February 7, 2022

Early Registration Deadline

April 2 – 5, 2022

ASPET Annual Meeting at EB 2022

Thank you to our Annual Meeting partners:

jpet_banner
molpharm_banner
dmd_banner
pharmrev_banner